Nichole Carlson
Concepts (572)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoidosis, Pulmonary | 5 | 2026 | 100 | 2.440 |
Why?
| | Tomography, X-Ray Computed | 8 | 2026 | 2786 | 1.940 |
Why?
| | Sarcoidosis | 3 | 2026 | 164 | 1.680 |
Why?
| | Bayes Theorem | 6 | 2020 | 426 | 1.150 |
Why?
| | Lung | 8 | 2026 | 4122 | 1.130 |
Why?
| | Luteinizing Hormone | 11 | 2020 | 206 | 0.990 |
Why?
| | Outpatients | 8 | 2025 | 440 | 0.950 |
Why?
| | Models, Statistical | 6 | 2020 | 669 | 0.900 |
Why?
| | Parkinson Disease | 5 | 2026 | 614 | 0.870 |
Why?
| | Hydrocortisone | 6 | 2015 | 303 | 0.840 |
Why?
| | Radiography, Thoracic | 3 | 2026 | 174 | 0.810 |
Why?
| | Hormones | 3 | 2017 | 134 | 0.770 |
Why?
| | Emphysema | 1 | 2023 | 100 | 0.730 |
Why?
| | Hypothalamo-Hypophyseal System | 7 | 2017 | 204 | 0.670 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 276 | 0.640 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2025 | 778 | 0.620 |
Why?
| | Diabetes Complications | 1 | 2022 | 219 | 0.620 |
Why?
| | Data Interpretation, Statistical | 3 | 2017 | 368 | 0.620 |
Why?
| | Cognitive Dysfunction | 1 | 2026 | 481 | 0.610 |
Why?
| | Alzheimer Disease | 6 | 2026 | 641 | 0.590 |
Why?
| | Disease Susceptibility | 1 | 2021 | 339 | 0.580 |
Why?
| | Metadata | 1 | 2018 | 17 | 0.550 |
Why?
| | Humans | 106 | 2026 | 146342 | 0.540 |
Why?
| | State Health Plans | 2 | 2008 | 28 | 0.530 |
Why?
| | Computer Simulation | 4 | 2017 | 1014 | 0.530 |
Why?
| | Models, Biological | 3 | 2017 | 1761 | 0.500 |
Why?
| | Ovary | 3 | 2017 | 236 | 0.500 |
Why?
| | Follicle Stimulating Hormone | 9 | 2023 | 265 | 0.500 |
Why?
| | Middle Aged | 45 | 2026 | 36619 | 0.490 |
Why?
| | Female | 79 | 2026 | 79499 | 0.480 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2015 | 145 | 0.480 |
Why?
| | Genome | 1 | 2018 | 307 | 0.470 |
Why?
| | Reproduction | 1 | 2017 | 209 | 0.470 |
Why?
| | Adult | 58 | 2026 | 41087 | 0.460 |
Why?
| | Child Health Services | 2 | 2008 | 189 | 0.450 |
Why?
| | Residence Characteristics | 6 | 2010 | 385 | 0.440 |
Why?
| | Wound Infection | 2 | 2026 | 60 | 0.440 |
Why?
| | Aged | 32 | 2026 | 26432 | 0.440 |
Why?
| | Contraceptives, Oral, Combined | 7 | 2011 | 18 | 0.430 |
Why?
| | Cluster Analysis | 3 | 2026 | 496 | 0.420 |
Why?
| | Health Services for the Aged | 2 | 2019 | 73 | 0.410 |
Why?
| | Biometry | 2 | 2017 | 67 | 0.410 |
Why?
| | Adenosine Monophosphate | 2 | 2025 | 87 | 0.410 |
Why?
| | Male | 52 | 2026 | 73396 | 0.410 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2021 | 640 | 0.410 |
Why?
| | Brain Injuries | 5 | 2010 | 499 | 0.410 |
Why?
| | Software | 2 | 2019 | 676 | 0.410 |
Why?
| | Alanine | 2 | 2025 | 171 | 0.400 |
Why?
| | Computational Biology | 1 | 2018 | 678 | 0.400 |
Why?
| | Obesity | 12 | 2023 | 3131 | 0.400 |
Why?
| | Pulsatile Flow | 1 | 2013 | 62 | 0.380 |
Why?
| | Antiparkinson Agents | 3 | 2009 | 41 | 0.380 |
Why?
| | Environment Design | 3 | 2010 | 26 | 0.380 |
Why?
| | Respiratory Function Tests | 3 | 2026 | 543 | 0.380 |
Why?
| | Dehydroepiandrosterone | 1 | 2013 | 50 | 0.370 |
Why?
| | Antibodies, Viral | 5 | 2024 | 689 | 0.370 |
Why?
| | Antibodies, Monoclonal | 6 | 2025 | 1512 | 0.370 |
Why?
| | Circadian Rhythm | 4 | 2013 | 515 | 0.370 |
Why?
| | Neuropsychological Tests | 4 | 2026 | 1149 | 0.340 |
Why?
| | Health Services Accessibility | 4 | 2010 | 1107 | 0.340 |
Why?
| | Specimen Handling | 1 | 2013 | 178 | 0.340 |
Why?
| | Antibodies, Neutralizing | 5 | 2025 | 348 | 0.330 |
Why?
| | Gonadotropins | 3 | 2023 | 44 | 0.330 |
Why?
| | Saliva | 1 | 2013 | 256 | 0.330 |
Why?
| | Walking | 4 | 2010 | 546 | 0.320 |
Why?
| | Antiviral Agents | 3 | 2025 | 779 | 0.310 |
Why?
| | Hospitalization | 9 | 2025 | 2475 | 0.310 |
Why?
| | White Matter | 2 | 2023 | 169 | 0.310 |
Why?
| | Levodopa | 2 | 2007 | 40 | 0.300 |
Why?
| | Hypogonadism | 2 | 2015 | 89 | 0.300 |
Why?
| | Oregon | 8 | 2011 | 83 | 0.300 |
Why?
| | Health Status | 4 | 2026 | 827 | 0.300 |
Why?
| | Endocrine System | 1 | 2009 | 23 | 0.290 |
Why?
| | Statistics as Topic | 3 | 2025 | 279 | 0.290 |
Why?
| | Activities of Daily Living | 3 | 2010 | 442 | 0.290 |
Why?
| | Risk Factors | 12 | 2026 | 10921 | 0.290 |
Why?
| | Reproducibility of Results | 4 | 2026 | 3416 | 0.280 |
Why?
| | Testosterone | 2 | 2010 | 419 | 0.280 |
Why?
| | Aging | 5 | 2026 | 1996 | 0.280 |
Why?
| | Cohort Studies | 8 | 2026 | 6077 | 0.270 |
Why?
| | Prenatal Care | 1 | 2010 | 310 | 0.270 |
Why?
| | Technology | 1 | 2009 | 100 | 0.270 |
Why?
| | Estradiol | 6 | 2023 | 517 | 0.260 |
Why?
| | Aged, 80 and over | 13 | 2026 | 8391 | 0.260 |
Why?
| | Cerebral Ventricles | 1 | 2007 | 56 | 0.260 |
Why?
| | Levonorgestrel | 4 | 2011 | 34 | 0.260 |
Why?
| | Metrorrhagia | 3 | 2011 | 4 | 0.260 |
Why?
| | Health Behavior | 3 | 2010 | 802 | 0.250 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2022 | 2623 | 0.250 |
Why?
| | Cognition Disorders | 3 | 2008 | 559 | 0.250 |
Why?
| | Perception | 2 | 2007 | 373 | 0.250 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2007 | 59 | 0.240 |
Why?
| | Methylphenidate | 1 | 2007 | 48 | 0.240 |
Why?
| | Spirometry | 3 | 2026 | 234 | 0.240 |
Why?
| | Smoking Cessation | 1 | 2010 | 442 | 0.240 |
Why?
| | Young Adult | 15 | 2024 | 14330 | 0.240 |
Why?
| | War-Related Injuries | 1 | 2026 | 46 | 0.230 |
Why?
| | Time Factors | 13 | 2017 | 7109 | 0.220 |
Why?
| | Poverty | 2 | 2010 | 530 | 0.210 |
Why?
| | Gliosis | 2 | 2023 | 30 | 0.210 |
Why?
| | Longitudinal Studies | 10 | 2020 | 3017 | 0.210 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2022 | 3930 | 0.210 |
Why?
| | Retrospective Studies | 15 | 2026 | 17438 | 0.210 |
Why?
| | Hyperoxia | 1 | 2026 | 126 | 0.210 |
Why?
| | Health Care Rationing | 1 | 2024 | 54 | 0.200 |
Why?
| | Brain Ischemia | 2 | 2017 | 362 | 0.200 |
Why?
| | Risk Assessment | 3 | 2026 | 3712 | 0.200 |
Why?
| | Disease Progression | 4 | 2026 | 2867 | 0.200 |
Why?
| | Denmark | 2 | 2021 | 51 | 0.200 |
Why?
| | Neurology | 1 | 2025 | 107 | 0.200 |
Why?
| | Healthcare Disparities | 1 | 2010 | 733 | 0.200 |
Why?
| | Medicaid | 1 | 2008 | 477 | 0.190 |
Why?
| | Oocytes | 2 | 2020 | 186 | 0.180 |
Why?
| | Proportional Hazards Models | 4 | 2025 | 1331 | 0.180 |
Why?
| | Socioeconomic Factors | 5 | 2010 | 1327 | 0.180 |
Why?
| | Body Mass Index | 6 | 2019 | 2458 | 0.180 |
Why?
| | Benchmarking | 1 | 2023 | 193 | 0.180 |
Why?
| | Pulmonary Fibrosis | 1 | 2026 | 395 | 0.180 |
Why?
| | Markov Chains | 3 | 2017 | 129 | 0.170 |
Why?
| | Monte Carlo Method | 3 | 2017 | 151 | 0.170 |
Why?
| | Disability Evaluation | 4 | 2018 | 297 | 0.170 |
Why?
| | Artificial Intelligence | 1 | 2026 | 389 | 0.170 |
Why?
| | Prospective Studies | 9 | 2023 | 8123 | 0.170 |
Why?
| | Cross-Sectional Studies | 12 | 2018 | 5899 | 0.170 |
Why?
| | Respiration, Artificial | 1 | 2026 | 711 | 0.160 |
Why?
| | Clinical Trials as Topic | 1 | 2026 | 1064 | 0.160 |
Why?
| | Oxygen | 1 | 2026 | 997 | 0.160 |
Why?
| | Doxycycline | 2 | 2011 | 61 | 0.160 |
Why?
| | Ethinyl Estradiol | 2 | 2011 | 16 | 0.160 |
Why?
| | Preimplantation Diagnosis | 1 | 2020 | 7 | 0.160 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 102 | 0.160 |
Why?
| | Oocyte Donation | 1 | 2020 | 6 | 0.160 |
Why?
| | Healthy Aging | 1 | 2021 | 44 | 0.160 |
Why?
| | Prescription Drugs | 1 | 2022 | 110 | 0.160 |
Why?
| | Weight Gain | 2 | 2022 | 562 | 0.160 |
Why?
| | Memory, Episodic | 1 | 2021 | 58 | 0.160 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2021 | 124 | 0.160 |
Why?
| | Proton Pump Inhibitors | 2 | 2017 | 101 | 0.150 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2020 | 48 | 0.150 |
Why?
| | Apomorphine | 3 | 2009 | 6 | 0.150 |
Why?
| | Cross-Over Studies | 6 | 2025 | 615 | 0.150 |
Why?
| | Myocardial Infarction | 2 | 2017 | 1215 | 0.150 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 206 | 0.150 |
Why?
| | Intensive Care Units | 1 | 2026 | 925 | 0.150 |
Why?
| | Fractals | 1 | 2019 | 8 | 0.150 |
Why?
| | Comprehensive Health Care | 1 | 2019 | 24 | 0.150 |
Why?
| | Menstruation | 2 | 1991 | 44 | 0.150 |
Why?
| | Radial Nerve | 1 | 1999 | 10 | 0.150 |
Why?
| | Nerve Compression Syndromes | 1 | 1999 | 23 | 0.150 |
Why?
| | Severity of Illness Index | 7 | 2024 | 2921 | 0.150 |
Why?
| | Internet | 2 | 2018 | 660 | 0.150 |
Why?
| | Aromatase Inhibitors | 1 | 2020 | 81 | 0.150 |
Why?
| | Human Growth Hormone | 2 | 2014 | 46 | 0.150 |
Why?
| | Astrocytes | 1 | 2021 | 229 | 0.140 |
Why?
| | Hip Fractures | 1 | 2019 | 88 | 0.140 |
Why?
| | Vital Capacity | 1 | 2019 | 293 | 0.140 |
Why?
| | Machine Learning | 1 | 2024 | 594 | 0.140 |
Why?
| | Hypoxia | 1 | 2026 | 1211 | 0.140 |
Why?
| | Datasets as Topic | 1 | 2018 | 120 | 0.140 |
Why?
| | Biomedical Research | 1 | 2025 | 729 | 0.140 |
Why?
| | Quality of Life | 5 | 2018 | 3200 | 0.130 |
Why?
| | Bibliometrics | 1 | 2018 | 68 | 0.130 |
Why?
| | Sheep, Domestic | 1 | 2017 | 33 | 0.130 |
Why?
| | Regression Analysis | 2 | 2019 | 999 | 0.130 |
Why?
| | Case-Control Studies | 5 | 2021 | 3647 | 0.130 |
Why?
| | Anxiety | 1 | 2025 | 1125 | 0.130 |
Why?
| | Wounds and Injuries | 1 | 2026 | 959 | 0.130 |
Why?
| | Contraception | 2 | 1991 | 170 | 0.130 |
Why?
| | Eligibility Determination | 2 | 2008 | 73 | 0.130 |
Why?
| | Reproductive Physiological Phenomena | 1 | 2017 | 2 | 0.130 |
Why?
| | Rhinitis | 2 | 2010 | 159 | 0.130 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 745 | 0.130 |
Why?
| | Medically Uninsured | 2 | 2008 | 134 | 0.130 |
Why?
| | Adolescent | 14 | 2024 | 22557 | 0.120 |
Why?
| | Algorithms | 3 | 2017 | 1849 | 0.120 |
Why?
| | Biomarkers | 5 | 2026 | 4340 | 0.120 |
Why?
| | Metabolic Diseases | 1 | 2018 | 114 | 0.120 |
Why?
| | Psychomotor Performance | 3 | 2009 | 329 | 0.120 |
Why?
| | Family Planning Services | 2 | 2008 | 93 | 0.120 |
Why?
| | Lactation | 1 | 2018 | 193 | 0.120 |
Why?
| | Hypothyroidism | 2 | 2007 | 68 | 0.120 |
Why?
| | Sinusitis | 2 | 2010 | 221 | 0.120 |
Why?
| | Premature Birth | 1 | 2020 | 390 | 0.120 |
Why?
| | Affect | 3 | 2008 | 318 | 0.120 |
Why?
| | Endoscopy | 2 | 2010 | 316 | 0.120 |
Why?
| | Ukraine | 2 | 2026 | 37 | 0.120 |
Why?
| | Low Back Pain | 1 | 2018 | 109 | 0.120 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2018 | 178 | 0.120 |
Why?
| | Double-Blind Method | 7 | 2011 | 2070 | 0.120 |
Why?
| | Pregnancy | 8 | 2023 | 7230 | 0.120 |
Why?
| | Dietary Fats | 1 | 2018 | 307 | 0.120 |
Why?
| | Antibodies | 1 | 2018 | 400 | 0.120 |
Why?
| | Models, Animal | 1 | 2017 | 387 | 0.120 |
Why?
| | Immunologic Memory | 1 | 2018 | 369 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2021 | 387 | 0.110 |
Why?
| | Brain | 6 | 2023 | 2991 | 0.110 |
Why?
| | Personnel Selection | 1 | 2016 | 90 | 0.110 |
Why?
| | Pulmonary Diffusing Capacity | 2 | 2026 | 78 | 0.110 |
Why?
| | Recovery of Function | 2 | 2010 | 725 | 0.110 |
Why?
| | Otolaryngology | 1 | 2016 | 106 | 0.110 |
Why?
| | Patient Dropouts | 1 | 2015 | 65 | 0.110 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2015 | 124 | 0.110 |
Why?
| | Growth Hormone-Secreting Pituitary Adenoma | 1 | 2014 | 12 | 0.110 |
Why?
| | Acromegaly | 1 | 2014 | 17 | 0.100 |
Why?
| | Pulmonary Embolism | 1 | 2017 | 246 | 0.100 |
Why?
| | Inflammation | 1 | 2026 | 2919 | 0.100 |
Why?
| | Pituitary-Adrenal System | 3 | 2013 | 169 | 0.100 |
Why?
| | Analysis of Variance | 5 | 2009 | 1298 | 0.100 |
Why?
| | Menstrual Cycle | 3 | 2011 | 145 | 0.100 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2015 | 145 | 0.100 |
Why?
| | Gonadotropin-Releasing Hormone | 4 | 2020 | 215 | 0.100 |
Why?
| | Breast Feeding | 1 | 2018 | 447 | 0.100 |
Why?
| | Drug Administration Schedule | 4 | 2010 | 790 | 0.100 |
Why?
| | Antibody Formation | 2 | 2022 | 290 | 0.100 |
Why?
| | Health Care Costs | 1 | 2017 | 423 | 0.100 |
Why?
| | Secretory Rate | 1 | 2013 | 12 | 0.100 |
Why?
| | Dementia | 2 | 2008 | 324 | 0.090 |
Why?
| | Health Policy | 2 | 2024 | 399 | 0.090 |
Why?
| | Decision Support Systems, Clinical | 1 | 2017 | 279 | 0.090 |
Why?
| | Electronics | 1 | 2013 | 65 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 197 | 0.090 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1185 | 0.090 |
Why?
| | Arrhythmias, Cardiac | 1 | 2015 | 358 | 0.090 |
Why?
| | Neurosurgical Procedures | 1 | 2014 | 209 | 0.090 |
Why?
| | Adenoma | 1 | 2014 | 210 | 0.090 |
Why?
| | Medical Records | 1 | 2013 | 193 | 0.090 |
Why?
| | Pandemics | 1 | 2021 | 1707 | 0.090 |
Why?
| | Age Factors | 8 | 2018 | 3347 | 0.090 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 391 | 0.090 |
Why?
| | Research Design | 3 | 2026 | 1143 | 0.090 |
Why?
| | Interviews as Topic | 3 | 2010 | 930 | 0.090 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 541 | 0.090 |
Why?
| | Urban Health | 2 | 2009 | 95 | 0.090 |
Why?
| | Wakefulness | 1 | 2013 | 170 | 0.080 |
Why?
| | Treatment Outcome | 8 | 2024 | 11821 | 0.080 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 568 | 0.080 |
Why?
| | Progestins | 1 | 2011 | 67 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2015 | 587 | 0.080 |
Why?
| | Equipment Design | 1 | 2013 | 520 | 0.080 |
Why?
| | Follow-Up Studies | 5 | 2017 | 5439 | 0.080 |
Why?
| | Memory | 3 | 2008 | 298 | 0.080 |
Why?
| | Dopamine Agonists | 2 | 2008 | 41 | 0.080 |
Why?
| | Amenorrhea | 1 | 2011 | 35 | 0.080 |
Why?
| | Contraceptives, Oral, Hormonal | 2 | 2007 | 30 | 0.080 |
Why?
| | Cytokines | 2 | 2015 | 2081 | 0.080 |
Why?
| | Birth Certificates | 1 | 2010 | 12 | 0.080 |
Why?
| | Estrone | 1 | 2010 | 41 | 0.080 |
Why?
| | Insulin | 1 | 2022 | 2525 | 0.080 |
Why?
| | Dihydrotestosterone | 1 | 2010 | 40 | 0.080 |
Why?
| | Birth Rate | 2 | 2020 | 32 | 0.080 |
Why?
| | Cognition | 3 | 2008 | 1292 | 0.080 |
Why?
| | Electronic Health Records | 3 | 2026 | 1210 | 0.080 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2010 | 16 | 0.080 |
Why?
| | Automobile Driving | 2 | 2010 | 157 | 0.080 |
Why?
| | Geographic Information Systems | 2 | 2010 | 45 | 0.080 |
Why?
| | Diet | 1 | 2018 | 1273 | 0.080 |
Why?
| | Live Birth | 2 | 2020 | 81 | 0.080 |
Why?
| | Pregnancy Rate | 2 | 2020 | 83 | 0.080 |
Why?
| | Thyroxine | 2 | 2007 | 67 | 0.080 |
Why?
| | Colorado | 3 | 2025 | 4595 | 0.080 |
Why?
| | Fertilization in Vitro | 2 | 2020 | 109 | 0.070 |
Why?
| | Cities | 1 | 2010 | 140 | 0.070 |
Why?
| | Sex Factors | 5 | 2018 | 2107 | 0.070 |
Why?
| | Personality | 1 | 2011 | 132 | 0.070 |
Why?
| | Electrical Equipment and Supplies | 1 | 2009 | 7 | 0.070 |
Why?
| | Abortion, Induced | 2 | 2008 | 112 | 0.070 |
Why?
| | Rehabilitation Centers | 1 | 2009 | 39 | 0.070 |
Why?
| | United States | 6 | 2020 | 16136 | 0.070 |
Why?
| | Pattern Recognition, Automated | 1 | 2009 | 74 | 0.070 |
Why?
| | Telecommunications | 1 | 2009 | 19 | 0.070 |
Why?
| | Progesterone | 3 | 2015 | 214 | 0.070 |
Why?
| | Independent Living | 1 | 2010 | 114 | 0.070 |
Why?
| | Registries | 1 | 2017 | 2400 | 0.070 |
Why?
| | Drug Interactions | 2 | 2007 | 405 | 0.070 |
Why?
| | Rural Health | 1 | 2009 | 87 | 0.070 |
Why?
| | Stroke | 1 | 2017 | 1287 | 0.070 |
Why?
| | Postmenopause | 1 | 2010 | 394 | 0.070 |
Why?
| | Mortality | 1 | 2011 | 375 | 0.070 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 7 | 0.070 |
Why?
| | Monitoring, Ambulatory | 1 | 2009 | 88 | 0.070 |
Why?
| | Anti-Bacterial Agents | 2 | 2026 | 1942 | 0.070 |
Why?
| | Logistic Models | 2 | 2010 | 2126 | 0.070 |
Why?
| | Ointments | 1 | 2007 | 24 | 0.070 |
Why?
| | Povidone-Iodine | 1 | 2007 | 12 | 0.070 |
Why?
| | Life Change Events | 1 | 2009 | 144 | 0.070 |
Why?
| | Vaccinia | 1 | 2007 | 20 | 0.070 |
Why?
| | Smallpox Vaccine | 1 | 2007 | 23 | 0.070 |
Why?
| | Foot | 1 | 2009 | 109 | 0.070 |
Why?
| | Vaccinia virus | 1 | 2007 | 35 | 0.070 |
Why?
| | Pregnancy, Unplanned | 1 | 2008 | 48 | 0.070 |
Why?
| | CD4 Lymphocyte Count | 2 | 2020 | 280 | 0.060 |
Why?
| | Exercise | 3 | 2010 | 2213 | 0.060 |
Why?
| | Child, Preschool | 4 | 2018 | 11913 | 0.060 |
Why?
| | Parkinsonian Disorders | 1 | 2007 | 43 | 0.060 |
Why?
| | Counseling | 1 | 2010 | 406 | 0.060 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 2007 | 14 | 0.060 |
Why?
| | Population Surveillance | 1 | 2010 | 481 | 0.060 |
Why?
| | Atrophy | 1 | 2007 | 199 | 0.060 |
Why?
| | Antibodies, Bacterial | 1 | 2007 | 147 | 0.060 |
Why?
| | Antigens, Bacterial | 1 | 2007 | 125 | 0.060 |
Why?
| | Movement | 1 | 2009 | 290 | 0.060 |
Why?
| | Antigens, Viral | 1 | 2007 | 186 | 0.060 |
Why?
| | Time Perception | 1 | 2007 | 31 | 0.060 |
Why?
| | Albumins | 1 | 2007 | 120 | 0.060 |
Why?
| | Awareness | 1 | 2007 | 113 | 0.060 |
Why?
| | Chemokine CXCL5 | 1 | 2026 | 20 | 0.060 |
Why?
| | Tremor | 1 | 2007 | 98 | 0.060 |
Why?
| | Chemokine CXCL9 | 1 | 2026 | 38 | 0.060 |
Why?
| | Wounds, Gunshot | 1 | 2009 | 262 | 0.060 |
Why?
| | Suicide, Attempted | 1 | 2009 | 391 | 0.060 |
Why?
| | Hospitals, Community | 1 | 2026 | 68 | 0.060 |
Why?
| | Cost-Benefit Analysis | 1 | 2009 | 640 | 0.060 |
Why?
| | Internship and Residency | 1 | 2016 | 1281 | 0.060 |
Why?
| | Blood-Brain Barrier | 1 | 2007 | 169 | 0.060 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2026 | 135 | 0.060 |
Why?
| | Utah | 1 | 2025 | 82 | 0.060 |
Why?
| | Paroxetine | 1 | 2005 | 8 | 0.060 |
Why?
| | Warfare | 1 | 2026 | 99 | 0.060 |
Why?
| | Treatment Failure | 2 | 2022 | 361 | 0.060 |
Why?
| | Infant | 3 | 2010 | 10114 | 0.060 |
Why?
| | Attitude to Health | 1 | 2008 | 421 | 0.050 |
Why?
| | Animals | 7 | 2023 | 38107 | 0.050 |
Why?
| | Emergency Service, Hospital | 1 | 2017 | 2363 | 0.050 |
Why?
| | Neurologic Examination | 2 | 2008 | 129 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2026 | 417 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1998 | 0.050 |
Why?
| | Sexual Behavior | 1 | 2008 | 490 | 0.050 |
Why?
| | Administration, Oral | 1 | 2007 | 872 | 0.050 |
Why?
| | Length of Stay | 2 | 2026 | 1358 | 0.050 |
Why?
| | Health Promotion | 1 | 2010 | 786 | 0.050 |
Why?
| | Patient Compliance | 1 | 2008 | 589 | 0.050 |
Why?
| | Video Recording | 1 | 2025 | 219 | 0.050 |
Why?
| | Likelihood Functions | 2 | 2017 | 138 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 208 | 0.050 |
Why?
| | Follicle Stimulating Hormone, Human | 1 | 2023 | 14 | 0.050 |
Why?
| | Child | 5 | 2018 | 22693 | 0.050 |
Why?
| | Amyloid beta-Peptides | 1 | 2026 | 251 | 0.050 |
Why?
| | Linear Models | 2 | 2020 | 857 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2026 | 1763 | 0.050 |
Why?
| | Neurites | 1 | 2023 | 51 | 0.050 |
Why?
| | Family | 1 | 2008 | 690 | 0.050 |
Why?
| | Diffusion Tensor Imaging | 1 | 2023 | 83 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 704 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2026 | 781 | 0.050 |
Why?
| | Physical Fitness | 1 | 2004 | 209 | 0.050 |
Why?
| | Vaccines | 1 | 2007 | 389 | 0.050 |
Why?
| | Ritonavir | 1 | 2023 | 76 | 0.050 |
Why?
| | Temporomandibular Joint Dysfunction Syndrome | 1 | 2002 | 3 | 0.050 |
Why?
| | Emotions | 1 | 2007 | 559 | 0.050 |
Why?
| | Facial Pain | 1 | 2002 | 12 | 0.040 |
Why?
| | Physical Examination | 2 | 2018 | 237 | 0.040 |
Why?
| | Acids | 1 | 2002 | 17 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2007 | 887 | 0.040 |
Why?
| | Administration, Cutaneous | 2 | 2015 | 128 | 0.040 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2023 | 158 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2007 | 801 | 0.040 |
Why?
| | Urban Population | 1 | 2025 | 497 | 0.040 |
Why?
| | Odds Ratio | 3 | 2010 | 1077 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2026 | 784 | 0.040 |
Why?
| | Faculty, Medical | 1 | 2025 | 309 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1408 | 0.040 |
Why?
| | Ovarian Follicle | 1 | 2002 | 78 | 0.040 |
Why?
| | Rheumatoid Factor | 1 | 2022 | 177 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 172 | 0.040 |
Why?
| | Neuroimaging | 1 | 2023 | 307 | 0.040 |
Why?
| | Puberty | 1 | 2002 | 141 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 3 | 2008 | 3926 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2025 | 1051 | 0.040 |
Why?
| | Pregnancy, Multiple | 1 | 2020 | 19 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2022 | 205 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2022 | 284 | 0.040 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2022 | 129 | 0.040 |
Why?
| | Leadership | 1 | 2025 | 414 | 0.040 |
Why?
| | Oocyte Retrieval | 1 | 2020 | 20 | 0.040 |
Why?
| | Leptin | 1 | 2002 | 248 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 2007 | 881 | 0.040 |
Why?
| | Blastocyst | 1 | 2020 | 50 | 0.040 |
Why?
| | Fasting | 1 | 2002 | 280 | 0.040 |
Why?
| | Embryo Transfer | 1 | 2020 | 45 | 0.040 |
Why?
| | Prostaglandins | 1 | 2000 | 94 | 0.040 |
Why?
| | Surveys and Questionnaires | 3 | 2025 | 6073 | 0.040 |
Why?
| | Radionuclide Imaging | 1 | 2019 | 116 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2009 | 2022 | 0.040 |
Why?
| | Breast Neoplasms | 2 | 2011 | 2418 | 0.040 |
Why?
| | Critical Illness | 1 | 2026 | 908 | 0.040 |
Why?
| | Vaccination | 2 | 2024 | 1449 | 0.040 |
Why?
| | Endotoxins | 1 | 2000 | 215 | 0.040 |
Why?
| | Decompression, Surgical | 1 | 1999 | 115 | 0.030 |
Why?
| | Oligodendroglia | 1 | 2001 | 198 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2007 | 1408 | 0.030 |
Why?
| | Receptors, Nicotinic | 1 | 2001 | 337 | 0.030 |
Why?
| | Immunization, Secondary | 1 | 2018 | 94 | 0.030 |
Why?
| | Depression | 1 | 2008 | 1575 | 0.030 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 2113 | 0.030 |
Why?
| | Depressive Disorder | 1 | 2000 | 361 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2022 | 901 | 0.030 |
Why?
| | Milk | 1 | 2018 | 117 | 0.030 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 15 | 0.030 |
Why?
| | Confidence Intervals | 2 | 2008 | 329 | 0.030 |
Why?
| | Biostatistics | 1 | 2017 | 19 | 0.030 |
Why?
| | Protons | 1 | 2017 | 96 | 0.030 |
Why?
| | Psychological Tests | 1 | 2018 | 127 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 492 | 0.030 |
Why?
| | Signal-To-Noise Ratio | 1 | 2017 | 71 | 0.030 |
Why?
| | Electromyography | 1 | 1999 | 428 | 0.030 |
Why?
| | Incidence | 2 | 2017 | 2936 | 0.030 |
Why?
| | Thyrotropin | 2 | 2007 | 120 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 267 | 0.030 |
Why?
| | Stem Cells | 1 | 2001 | 613 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 992 | 0.030 |
Why?
| | Health Surveys | 2 | 2009 | 511 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2000 | 861 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 846 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1378 | 0.030 |
Why?
| | Viruses | 1 | 2018 | 165 | 0.030 |
Why?
| | Drug Combinations | 2 | 2011 | 400 | 0.030 |
Why?
| | Escherichia coli | 1 | 2000 | 832 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2015 | 60 | 0.030 |
Why?
| | Telemedicine | 1 | 2025 | 966 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2017 | 220 | 0.030 |
Why?
| | Fatty Liver | 1 | 2018 | 252 | 0.030 |
Why?
| | Neoplasms | 1 | 2011 | 2954 | 0.030 |
Why?
| | Systole | 1 | 2015 | 179 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1503 | 0.030 |
Why?
| | Drug Users | 1 | 2015 | 43 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 1224 | 0.030 |
Why?
| | Electric Countershock | 1 | 2015 | 126 | 0.030 |
Why?
| | Risk | 1 | 2017 | 920 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2015 | 278 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 517 | 0.030 |
Why?
| | Phospholipids | 1 | 2015 | 215 | 0.030 |
Why?
| | Psychometrics | 1 | 2018 | 712 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2018 | 642 | 0.020 |
Why?
| | Phenotype | 1 | 2022 | 3206 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2015 | 397 | 0.020 |
Why?
| | Substance Abuse, Intravenous | 1 | 2015 | 131 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2015 | 778 | 0.020 |
Why?
| | Death, Sudden, Cardiac | 1 | 2015 | 242 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4580 | 0.020 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 1221 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 970 | 0.020 |
Why?
| | Estrogens | 1 | 2015 | 364 | 0.020 |
Why?
| | Follicular Phase | 2 | 2004 | 41 | 0.020 |
Why?
| | Mice, Inbred C57BL | 2 | 2018 | 6034 | 0.020 |
Why?
| | Fatty Acids | 1 | 2015 | 460 | 0.020 |
Why?
| | Feeding Behavior | 1 | 2018 | 692 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 772 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1543 | 0.020 |
Why?
| | Defibrillators, Implantable | 1 | 2015 | 393 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2018 | 665 | 0.020 |
Why?
| | Periodicity | 2 | 2001 | 57 | 0.020 |
Why?
| | Prognosis | 1 | 1999 | 4351 | 0.020 |
Why?
| | Abbreviated Injury Scale | 1 | 2010 | 28 | 0.020 |
Why?
| | Nasal Polyps | 1 | 2010 | 59 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2010 | 115 | 0.020 |
Why?
| | Life Expectancy | 1 | 2010 | 72 | 0.020 |
Why?
| | Amides | 1 | 2010 | 100 | 0.020 |
Why?
| | Heart-Assist Devices | 1 | 2015 | 572 | 0.020 |
Why?
| | Reference Values | 1 | 2010 | 796 | 0.020 |
Why?
| | Income | 1 | 2010 | 206 | 0.020 |
Why?
| | Glasgow Coma Scale | 1 | 2010 | 211 | 0.020 |
Why?
| | Obstetrics | 1 | 2011 | 179 | 0.020 |
Why?
| | Heart Transplantation | 1 | 2015 | 682 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 6460 | 0.020 |
Why?
| | Norgestrel | 1 | 1988 | 2 | 0.020 |
Why?
| | Medroxyprogesterone | 1 | 1988 | 11 | 0.020 |
Why?
| | Administration, Intravaginal | 1 | 1988 | 19 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 453 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 1150 | 0.020 |
Why?
| | Family Characteristics | 1 | 2010 | 203 | 0.020 |
Why?
| | Gynecology | 1 | 2011 | 185 | 0.020 |
Why?
| | Medroxyprogesterone Acetate | 1 | 1988 | 33 | 0.020 |
Why?
| | Poverty Areas | 1 | 2008 | 43 | 0.020 |
Why?
| | Thyroid Function Tests | 1 | 2008 | 19 | 0.020 |
Why?
| | Sheep | 2 | 2002 | 870 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 313 | 0.020 |
Why?
| | Intelligence Tests | 1 | 2008 | 55 | 0.020 |
Why?
| | Receptors, Dopamine | 1 | 2008 | 20 | 0.020 |
Why?
| | Parity | 1 | 1988 | 113 | 0.020 |
Why?
| | Smallpox | 1 | 2007 | 10 | 0.020 |
Why?
| | Galvanic Skin Response | 1 | 2007 | 26 | 0.020 |
Why?
| | Benzodioxoles | 1 | 2010 | 164 | 0.020 |
Why?
| | Diphtheria | 1 | 2007 | 21 | 0.020 |
Why?
| | Employment | 1 | 2010 | 180 | 0.020 |
Why?
| | Tetanus | 1 | 2007 | 29 | 0.020 |
Why?
| | Personal Satisfaction | 1 | 2010 | 218 | 0.020 |
Why?
| | Contraindications | 1 | 2007 | 88 | 0.020 |
Why?
| | Half-Life | 1 | 2007 | 157 | 0.020 |
Why?
| | Educational Status | 1 | 2010 | 466 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2007 | 167 | 0.020 |
Why?
| | Virus Shedding | 1 | 2007 | 54 | 0.020 |
Why?
| | Commerce | 1 | 2008 | 80 | 0.020 |
Why?
| | Cause of Death | 1 | 2010 | 456 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 576 | 0.020 |
Why?
| | Plasma Cells | 1 | 2007 | 80 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2007 | 171 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 504 | 0.020 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2007 | 47 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2007 | 55 | 0.020 |
Why?
| | Family Practice | 1 | 2011 | 422 | 0.020 |
Why?
| | Apolipoproteins E | 1 | 2007 | 97 | 0.020 |
Why?
| | Research | 1 | 2010 | 421 | 0.020 |
Why?
| | Photic Stimulation | 1 | 2007 | 265 | 0.020 |
Why?
| | Thyroid Hormones | 1 | 2007 | 69 | 0.020 |
Why?
| | Thyroid Gland | 1 | 2007 | 93 | 0.010 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2007 | 253 | 0.010 |
Why?
| | Cerebrovascular Disorders | 1 | 2007 | 103 | 0.010 |
Why?
| | Neural Inhibition | 1 | 2007 | 186 | 0.010 |
Why?
| | Safety | 1 | 2008 | 347 | 0.010 |
Why?
| | Age of Onset | 1 | 2008 | 558 | 0.010 |
Why?
| | Motor Skills | 1 | 2007 | 103 | 0.010 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2008 | 522 | 0.010 |
Why?
| | Patient Satisfaction | 1 | 2010 | 706 | 0.010 |
Why?
| | Dopamine Agents | 1 | 2005 | 22 | 0.010 |
Why?
| | Down-Regulation | 1 | 2007 | 614 | 0.010 |
Why?
| | Mental Recall | 1 | 2007 | 226 | 0.010 |
Why?
| | Virus Diseases | 1 | 2007 | 219 | 0.010 |
Why?
| | Gait Disorders, Neurologic | 1 | 2005 | 43 | 0.010 |
Why?
| | Comorbidity | 1 | 2010 | 1665 | 0.010 |
Why?
| | Vestibular Diseases | 1 | 2005 | 45 | 0.010 |
Why?
| | Inpatients | 1 | 2009 | 540 | 0.010 |
Why?
| | Memory, Short-Term | 1 | 2007 | 276 | 0.010 |
Why?
| | Dizziness | 1 | 2005 | 93 | 0.010 |
Why?
| | Self Efficacy | 1 | 2008 | 418 | 0.010 |
Why?
| | Presynaptic Terminals | 1 | 2005 | 89 | 0.010 |
Why?
| | Diet Records | 1 | 2004 | 87 | 0.010 |
Why?
| | Menarche | 1 | 2004 | 53 | 0.010 |
Why?
| | Chronic Disease | 1 | 2010 | 1827 | 0.010 |
Why?
| | Serotonin | 1 | 2005 | 297 | 0.010 |
Why?
| | Skin | 1 | 2007 | 701 | 0.010 |
Why?
| | Overweight | 1 | 2008 | 614 | 0.010 |
Why?
| | Dopamine | 1 | 2005 | 295 | 0.010 |
Why?
| | Stress, Psychological | 1 | 2011 | 1171 | 0.010 |
Why?
| | Follicular Fluid | 1 | 2002 | 5 | 0.010 |
Why?
| | Adrenal Cortex | 1 | 2002 | 33 | 0.010 |
Why?
| | Accidental Falls | 1 | 2005 | 227 | 0.010 |
Why?
| | Contraceptives, Oral | 1 | 2002 | 37 | 0.010 |
Why?
| | Neuraminidase | 1 | 2002 | 27 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 2002 | 32 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2002 | 165 | 0.010 |
Why?
| | Dipeptides | 1 | 2002 | 55 | 0.010 |
Why?
| | Heart Failure | 1 | 2015 | 2329 | 0.010 |
Why?
| | Thinness | 1 | 2002 | 100 | 0.010 |
Why?
| | Dihydro-beta-Erythroidine | 1 | 2001 | 6 | 0.010 |
Why?
| | Fura-2 | 1 | 2001 | 12 | 0.010 |
Why?
| | Postprandial Period | 1 | 2002 | 114 | 0.010 |
Why?
| | Nifedipine | 1 | 2001 | 27 | 0.010 |
Why?
| | Pituitary Gland | 1 | 2002 | 148 | 0.010 |
Why?
| | Nicotinic Antagonists | 1 | 2001 | 37 | 0.010 |
Why?
| | Energy Intake | 1 | 2004 | 507 | 0.010 |
Why?
| | Oxygen Consumption | 1 | 2004 | 721 | 0.010 |
Why?
| | Luteal Phase | 1 | 2000 | 51 | 0.010 |
Why?
| | Caregivers | 1 | 2010 | 1080 | 0.010 |
Why?
| | Area Under Curve | 1 | 2001 | 335 | 0.010 |
Why?
| | Prostaglandin Antagonists | 1 | 2000 | 3 | 0.010 |
Why?
| | Flurbiprofen | 1 | 2000 | 3 | 0.010 |
Why?
| | Depression, Chemical | 1 | 2000 | 16 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2002 | 391 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 165 | 0.010 |
Why?
| | HIV Infections | 1 | 2015 | 3215 | 0.010 |
Why?
| | Pain Measurement | 1 | 2002 | 573 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2001 | 340 | 0.010 |
Why?
| | Hypertension | 1 | 2007 | 1272 | 0.010 |
Why?
| | Fever | 1 | 2000 | 322 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2007 | 2488 | 0.010 |
Why?
| | Gene Expression | 1 | 2001 | 1463 | 0.010 |
Why?
| | Calcium | 1 | 2001 | 1181 | 0.010 |
Why?
| | Sleep | 1 | 2002 | 896 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2001 | 4118 | 0.010 |
Why?
| | Rats | 1 | 2001 | 5586 | 0.010 |
Why?
| | Neurons | 1 | 2001 | 1668 | 0.010 |
Why?
| | Mice | 1 | 2007 | 18297 | 0.000 |
Why?
|
|
Carlson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|